San Diego, Ca., USA - December 12, 2012, San Diego, Ca., USA - Sequenom, Inc., a life sciences company, announced he appointments of William Welch as president and COO and Dirk van den Boom as executive vice president of research and development and chief technology officer.
Article continues below
Mr. Welch joined Sequenom in January last year as Senior Vice President, Diagnostics. Prior to joining Sequenom, he was a consultant to molecular diagnostic companies in the personalized medicine sector. From August 2005 to September 2009, he was senior vice president and chief commercial officer at Monogram Biosciences, a bioscience laboratory services company.
Prior to his time at Monogram, Mr. Welch was vice president of sales and marketing at La Jolla Pharmaceuticals and vice president of global marketing with Dade Behring MicroScan. He entered the healthcare field with Abbott Laboratories where he held progressive management positions, including General Manager. He earned a B.S. with honors in chemical engineering from the University of California at Berkeley and received his M.B.A. from Harvard University.
Mr. van den Boom has served as Sequenom's Senior Vice President of research and development since August 2010 and previously served as the Company's vice president, research and development. He joined Sequenom in 1998 at the company's Hamburg office, subsequently serving in various management roles of increasing responsibility within the R&D department.
Mr. van den Boom received his Ph.D. in Biochemistry/Molecular Biology from the University of Hamburg where he focused on various aspects of nucleic acid analysis with mass spectrometry. Mr. van den Boom has co-authored more than 50 scientific articles and is an inventor on 48 patents or patent applications.
The company also announced that Ronald Lindsay has been named as the company's executive vice president of strategic planning.
Mr. Lindsay has been a director since 2003. Heserved as vice president, research and development, and chief science officer of diaDexus Inc., a biotechnology company, from 2000 to January 2004. From 1997 through 2000, Dr. Lindsay served in various senior management roles with Millennium Pharmaceuticals, a biopharmaceutical company. ■